Hepatocellular carcinoma
Conditions
Interventions
HAIC plus Camrelizumab plus Lenvatinib treatment group:None
Sponsors
Harbin Medical University Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age: 18 to 75 years old, no gender restrictions; 2. Patients with clinically confirmed hepatocellular carcinoma; 3. ECOG PS score: 0-2 points; 4. Patients have received at least three cycles of treatment; 5. Good treatment compliance, no severe diseases in other major organs. 6. Complete clinical records, comprehensive follow-up information, and timely clinical re-examination.
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating women; 2. History of other malignancies within the past 5 years, except for adequately treated cervical carcinoma in situ or squamous cell carcinoma of the skin, or well-controlled basal cell carcinoma of the skin; 3. Uncontrolled symptomatic brain metastases, history of uncontrollable psychiatric disorders, or severe intellectual or cognitive impairment; 4. Patients refusing follow-up or unable to be followed.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective response rate;Disease Control Rate;Overall survival;Incidence of adverse reactions; | — |
Countries
China
Contacts
Public ContactDong Wei
Harbin Medical University Cancer Hospital
Outcome results
None listed